Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.59 |
| ▸ | CASP6 | P55212 | 1/20 | 0.55 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20865720 | 0.84 | NPSR1 (0.45) | NPSR1NOTUMCASP6CYP11B2POLB | |
| SCHEMBL7165608 | 0.83 | NPSR1 (0.59) | NPSR1NOTUMCASP6POLBMEN1 | |
| SCHEMBL31457876 | 0.81 | NPSR1 (0.58) | NPSR1NOTUMCASP6CYP11B2POLB | |
| SCHEMBL10540017 | 0.81 | NPSR1 (0.58) | NPSR1NOTUMCASP6POLBMEN1 | |
| SCHEMBL9471223 | 0.81 | NPSR1 (0.58) | NPSR1NOTUMCASP6POLBMEN1 | |
| SCHEMBL17492500 | 0.81 | NPSR1 (0.68) | NPSR1CASP6POLBMEN1ALDH1A1 | |
| SCHEMBL9470187 | 0.78 | NPSR1 (0.54) | NPSR1NOTUMCASP6CYP11B2POLB | |
| SCHEMBL3071409 | 0.77 | HTR2A (0.56) | NPSR1CASP6POLBMEN1ALDH1A1 | |
| SCHEMBL21792321 | 0.77 | CYP11B2 (0.54) | NPSR1NOTUMCYP11B2POLBMEN1 | |
| SCHEMBL5334692 | 0.75 | NOTUM (0.51) | NPSR1NOTUMCYP11B2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3702354-B1 | COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY AND USE THEREOF | HAIHE BIOPHARMA CO LTD (CN) | 2024-05-22 | — | — | EP | disclosed |
| US-11465984-B2 | Compound having ERK kinase inhibitory activity and use thereof | SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) | 2022-10-11 | — | — | US | disclosed |
| WO-2021093795-A1 | ROCK INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 武汉朗来科技发展有限公司 | 2021-05-20 | — | — | WO | disclosed |
| EP-2903615-B1 | 5-PYRIDIN-3-YL-2,3-DIHYDRO-1H-INDOLE DERIVATIVES AS ALDOSTERONE SYNTHASE (CYP11B2) INHIBITORS FOR THE TREATMENT OF HYPERTENSION | MERCK SHARP & DOHME (US) | 2021-04-07 | — | — | EP | disclosed |
| EP-2903615-B1 | 5-PYRIDIN-3-YL-2,3-DIHYDRO-1H-INDOLE DERIVATIVES AS ALDOSTERONE SYNTHASE (CYP11B2) INHIBITORS FOR THE TREATMENT OF HYPERTENSION | MERCK SHARP & DOHME (US) | 2021-04-07 | — | — | EP | disclosed |
| EP-3702354-A1 | COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY AND USE THEREOF | Shanghai Haihe Pharmaceutical Co., Ltd. (CN) | 2020-09-02 | — | — | EP | disclosed |
| EP-3702354-A1 | COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY AND USE THEREOF | Shanghai Haihe Pharmaceutical Co., Ltd. (CN) | 2020-09-02 | — | — | EP | disclosed |
| US-20200247781-A1 | COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY AND USE THEREOF | HAIHE BIOPHARMA CO., LTD. (CN) | 2020-08-06 | — | — | US | disclosed |
| US-20200247781-A1 | COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY AND USE THEREOF | HAIHE BIOPHARMA CO., LTD. (CN) | 2020-08-06 | — | — | US | disclosed |
| WO-2019062949-A1 | COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY AND USE THEREOF | 上海海和药物研究开发有限公司 | 2019-04-04 | — | — | WO | disclosed |
| EP-2903615-A1 | INDOLINE COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITIORS RELATED APPLICATIONS | Merck Sharp & Dohme Corp. (US) | 2015-08-12 | — | — | EP | disclosed |
| WO-2014055595-A1 | INDOLINE COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITIORS RELATED APPLICATIONS | MERCK SHARP & DOHME CORP. (US) | 2014-04-10 | — | — | WO | disclosed |
| US-6525056-B2 | A fused nitrogen containing heterocyclic compound useful for treating psychiatric and neurological disorders, anxiety, post-traumatic stress, supranuclear palsy, feeding, immunological, cardiovascular and hypersensitivity disorders | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-25 | — | — | US | disclosed |
| EP-1012151-B1 | HETEROCYCLYL-SUBSTITUTED RING-FUSED PYRIDINES AND PYRIMIDINES AS CORTICOTROPIN RELEASING HORMONE (CRH) ANTAGONISTS, USEFUL FOR TREATING CNS AND STRESS-RELATED DISORDERS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2002-08-07 | — | — | EP | disclosed |
| US-20010025042-A1 | Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (CRH) antagonists, useful for treating cns and stress-related disorders | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2001-09-27 | — | — | US | disclosed |
| US-6245769-B1 | Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone(CRH) antagonists, useful for treating CNS and stress-related disorders | DUPONT PHARMACEUTICALS COMPANY | 2001-06-12 | — | — | US | disclosed |
| US-6228868-B1 | ANTICARCINOGENIC AND ANTITUMOR AGENTS | ABBOTT LABORATORIES | 2001-05-08 | — | — | US | disclosed |
| EP-1012151-A1 | HETEROCYCLYL-SUBSTITUTED RING-FUSED PYRIDINES AND PYRIMIDINES AS CORTICOTROPIN RELEASING HORMONE (CRH) ANTAGONISTS, USEFUL FOR TREATING CNS AND STRESS-RELATED DISORDERS | Dupont Pharmaceuticals Company (US) | 2000-06-28 | — | — | EP | disclosed |
| WO-2000006556-A1 | SUBSTITUTED OXAZOLINES AS ANTIPROLIFERATIVE AGENTS | ABBOTT LABORATORIES (US) | 2000-02-10 | — | — | WO | disclosed |
| WO-1999011643-A1 | HETEROCYCLYL-SUBSTITUTED RING-FUSED PYRIDINES AND PYRIMIDINES AS CORTICOTROPIN RELEASING HORMONE (CRH) ANTAGONISTS, USEFUL FOR TREATING CNS AND STRESS-RELATED DISORDERS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11465984-B2 | Compound having ERK kinase inhibitory activity and use thereof | MAPK1, MAPK4, MAPK7 | NPSR1 2796/4885NOTUM 1216/4885CASP6 2921/4885 |
| US-20200247781-A1 | COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY AND USE THEREOF | MAPK1, MAPK4, MAPK7 | NPSR1 2796/4885NOTUM 1216/4885CASP6 2921/4885 |
| US-20010025042-A1 | Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (CRH) antagonists, useful for treating cns and stress-related disorders | CRH, CRHR1, CRHR2 | NPSR1 81/4885NOTUM 4835/4885CASP6 2753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.